• database,DNA,genetic testing,genetics

EU Rules Could Restrict Genetic TestingGenetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments.

Read more

  • tHIS,Healthcare Event,API China

The World's Largest Healthcare Event -- tHIS Opens to Record Breaking Crowds in ShanghaiThe 2015 Health Industry Summit (tHIS), an event that is predicted to transform the Chinese healthcare industry sector, opened to huge crowds on May 15, with over 210,000 visitors from 150 countries in attendance.

Read more

  • Ebola,FDA,Tekmira,RNAi

Tekmira Pharmaceuticals is planning to resume its Phase I study of an investigational treatment for EbolaCanadian biotech Tekmira Pharmaceuticals ($TKMR) is planning to resume its Phase I study of an investigational treatment for Ebola now that the FDA has waved off some lingering safety concerns. The agency had effectively halted development of TKM-Ebola, an RNAi therapy

Read more

  • BioMarin,Shire,SHPG

Shire PLC (ADR) Eyes BioMarin Pharmaceutical Inc.BioMarin stock has rallied up 5% in extended trading on news that Shire is interested in acquiring the company Word on the Street is that Shire plc

Read more

  • Novartis,Japan,pharma business

Novartis faces suspension in Japan after series of trial datas candalsJapan plans to temporarily suspend Novartis' ($NVS) pharma business in that country, according to media reports. The Ministry of Health, Labour and Welfare's order will last about 15 days and will cite repeated violations of failure to report adverse events properly, the Japan Timessays.

Read more

  • VC Firms,Biotechs,venture capital

20 Top VC Firms for BiotechsThe stampede is back on among venture capital firms to raise new money and close more funds, after years of standing pat following the recession and years of sluggish recovery.Polaris Partners became the latest VC firm in the money

Read more

  • GSK,GlaxoSmithKline,Apollo

Apollo Global Management is planning to bid on GSK's entire portfolio of drugsGlaxoSmithKline ($GSK) has long explored a sale of some $3 billion worth of its older drugs, planning to shed products by geographic region to meet buyers' interests. Now, the company could have a more enticing offer on its hands as private equity firm Apollo Global Management is planning to bid on GSK's entire portfolio of drugs, people familiar with the process toldReuters.

Read more

  • Merck,FDA,Clostridium difficile,Bezlotoxumab

Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection RecurrenceMerck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

Read more

  • Sanofi,Regeneron,Sarilumab

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDASanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab.

Read more

  • BMS,HIV particles,HIV drug

First data backs efficacy of BMS' novel HIV drugA Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

Read more

  • CHMP,HIV-1,Edurant,adolescents

CHMP adopts positive opinion of Edurant in adolescents with HIV-1The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection

Read more

  • biotechnology industry,biotech company,clinical trials,Neos Therapeutics,Regulatory

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approvalNeos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Read more

  • SpringFestival,14th February,24th February

Chinese New Year holidayHoliday arrangements for Chinese SpringFestival. 14th February to 24th February(11days), 9th February will be adjusted towork.

Read more

  • 2014,Shanghai,CPhI & P-MEC China,Exhibition,cphi

Our company successfully exhibitors 2014 Shanghai CPhI & P-MEC ChinaOur company successfully exhibitors 2014 Shanghai CPhI & P-MEC China.

Read more

Categories

Recent News

Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab.

First data backs efficacy of BMS' novel HIV drug

A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

EU Rules Could Restrict Genetic Testing

Genetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments.

CHMP adopts positive opinion of Edurant in adolescents with HIV-1

The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.